Literature DB >> 33198924

Can Growth Factors Cure Parkinson's Disease?

Yulia A Sidorova1, Mart Saarma2.   

Abstract

Growth factors (GFs) hold considerable promise for disease modification in neurodegenerative disorders because they can protect and restore degenerating neurons and also enhance their functional activity. However, extensive efforts applied to utilize their therapeutic potential in humans have achieved limited success so far. Multiple clinical trials with GFs were performed in Parkinson's disease (PD) patients, in whom diagnostic symptoms of the disease are caused by advanced degeneration of nigrostriatal dopamine neurons (DNs), but the results of these trials are controversial. This review discusses recent developments in the field of therapeutic use of GFs, problems and obstacles related to this use, suggests the ways to overcome these issues, and alternative approaches that can be used to utilize the potential ofGFsin PD management.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Parkinson’s disease; dopamine neurons; glial cell line-derived neurotrophic factor family ligands; neurotrophic factors; neurturin, cerebral dopamine neurotrophic factor

Year:  2020        PMID: 33198924     DOI: 10.1016/j.tips.2020.09.010

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  13 in total

Review 1.  Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson's disease.

Authors:  Alcmène Chalazonitis; Meenakshi Rao; David Sulzer
Journal:  NPJ Parkinsons Dis       Date:  2022-04-22

2.  Small-Molecule Inhibitors of the RNA M6A Demethylases FTO Potently Support the Survival of Dopamine Neurons.

Authors:  Simona Selberg; Li-Ying Yu; Olesja Bondarenko; Esko Kankuri; Neinar Seli; Vera Kovaleva; Koit Herodes; Mart Saarma; Mati Karelson
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 3.  Probiotics and the Treatment of Parkinson's Disease: An Update.

Authors:  Hamed Mirzaei; Saman Sedighi; Ebrahim Kouchaki; Erfaneh Barati; Ehsan Dadgostar; Michael Aschner; Omid Reza Tamtaji
Journal:  Cell Mol Neurobiol       Date:  2021-07-20       Impact factor: 4.231

Review 4.  Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.

Authors:  Michael J Beckstead; Rebecca D Howell
Journal:  Exp Neurol       Date:  2021-03-20       Impact factor: 5.620

Review 5.  Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic.

Authors:  James A Conway; Edgar R Kramer
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

Review 6.  Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.

Authors:  Karen M Delgado-Minjares; Daniel Martinez-Fong; Irma A Martínez-Dávila; Cecilia Bañuelos; M E Gutierrez-Castillo; Víctor Manuel Blanco-Alvarez; Maria-Del-Carmen Cardenas-Aguayo; José Luna-Muñoz; Mar Pacheco-Herrero; Luis O Soto-Rojas
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 7.  Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.

Authors:  Della Grace Thomas Parambi; Khalid Saad Alharbi; Rajesh Kumar; Seetha Harilal; Gaber El-Saber Batiha; Natália Cruz-Martins; Omnia Magdy; Arafa Musa; Dibya Sundar Panda; Bijo Mathew
Journal:  Mol Neurobiol       Date:  2021-10-15       Impact factor: 5.682

Review 8.  Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.

Authors:  Päivi Lindholm; Mart Saarma
Journal:  Mol Psychiatry       Date:  2021-12-14       Impact factor: 13.437

Review 9.  Growth Factor Therapy for Parkinson's Disease: Alternative Delivery Systems.

Authors:  Sarah Jarrin; Abrar Hakami; Ben Newland; Eilís Dowd
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 10.  Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson's Disease.

Authors:  Vera Kovaleva; Mart Saarma
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.